secwatch.observer — SEC 8-K summary
======================================

Issuer:     Galera Therapeutics, Inc. (GRTX)
CIK:        0001563577
Form:       8-K
Filed at:   2024-03-28T23:59:59+00:00
Accession:  0001193125-24-079600
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Galera reports FY2023 net loss $59.1M; avasopasem NDA rejected; strategic review may lead to dissolution
--------------------------------------------------------------------------------

- FY2023 net loss $59.1M ($1.33/sh); Q4 net loss $5.6M ($0.10/sh); cash $18.3M as of Dec 31, 2023.
- Cash and equivalents $18.3M at year-end; expected to fund operations into Q2 2025.
- FDA issued CRL for avasopasem NDA in Aug 2023; requires additional Phase 3 trial for resubmission.
- Halted GRECO-2 (pancreatic) and GRECO-1 (NSCLC) trials after futility; workforce reduced 70% in Aug 2023.
- Engaged Stifel to review strategic alternatives; CEO notes process could lead to dissolution.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563577/000119312524079600/0001193125-24-079600-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563577/000119312524079600/d816795d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-079600

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer